All patients (n=50) | Fulfilling the criteria (n=21) | Not fulfilling the criteria (n=29) | P value | |
---|---|---|---|---|
Age (years, mean±SD) | 59.9±14.8 | 61.5±3.6 | 58.8±2.6 | 0.41 |
Female/male ratio | 1/49 | 1/20 | 0/29 | 0.42 |
Body mass index (kg/m2, mean±SD) | 27.0±3.3 | 27.5±3.4 | 26.6±2.6 | 0.41 |
Familiar history of gout [n (%)] | 14 (28.0%) | 6 (28.6%) | 8 (27.6%) | 0.94 |
Disease duration (years, mean±SD) | 6.5±6.6 | 5.9±5.7 | 6.8±7.2 | 0.96 |
Flares in the 12 months preceding the enrolment (mean±SD) | 0.8±1.0 | 0.6±0.9 | 0.8±1.0 | 0.25 |
Smoking habit—past smoker [n (%)] | 20 (40.0%) | 10 (47.6%) | 10 (34.5%) | 1.0 |
Smoking habit—current smoker [n (%)] | 7 (14.0%) | 3 (14.3%) | 4 (13.8%) | |
ULT—allopurinol [n (%)] | 34 (68.0%) | 14 (66.7%) | 20 (69.0%) | 0.86 |
ULT—febuxostat [n (%)] | 16 (32.0%) | 7 (33.3%) | 9 (31.0%) | |
Ongoing flare prophylaxis with colchicine [n (%)] | 27 (54.0%) | 7 (33.3%) | 20 (69.0%) | 0.02 |
Colchicine daily dose (mg, mean±SD) | 0.63±0.31 | 0.50±0.25 | 0.68±0.31 | 0.99 |
Duration of colchicine prophylaxis (months, mean±SD) | 9.9±2.2 | 9.3±2.5 | 10.1±2.1 | 0.45 |
C-reactive protein level (mg/dl, mean±SD) | 0.5±0.5 | 0.4±0.4 | 0.6±0.5 | 0.08 |
SU, highest level (μmol/l, mean±SD) | 511.5±95.2 | 487.7±119.0 | 535.3±71.4 | 0.36 |
SU, current level (μmol/l, mean±SD) | 298.4±53.5 | 285.5±59.5 | 300.3±53.5 | 0.16 |
Number of comorbidities (mean±SD) | 3.0±2.0 | 3.2±2.1 | 2.8±1.9 | 0.50 |
Dyslipidemia [n (%)] | 22 (44.0%) | 11 (52.4%) | 11 (37.9%) | 0.31 |
Arterial hypertension [n (%)] | 31 (62.0%) | 13 (61.9%) | 18 (62.1%) | 0.99 |
Ischemic heart disease/Stroke [n (%)] | 5 (10.0%) | 1 (4.8%) | 4 (13.8%) | 0.29 |
Atherosclerosis [n (%)] | 14 (28.0%) | 7 (33.3%) | 7 (24.1%) | 0.48 |
Nephrolithiasis [n (%)] | 3 (6.0%) | 0 | 3 (10.3%) | 0.13 |
CKD (eGFR <60 ml/min/1.73m2) [n (%)] | 8 (16.0%) | 3 (14.3%) | 5 (17.2%) | 0.78 |